Multi-Center Analysis of Liver Transplantation for Combined Hepatocellular Carcinoma-Cholangiocarcinoma Liver Tumors.
Aged
Carcinoma, Hepatocellular
/ mortality
Cholangiocarcinoma
/ mortality
Disease-Free Survival
Hepatectomy
/ statistics & numerical data
Humans
Kaplan-Meier Estimate
Liver Neoplasms
/ mortality
Liver Transplantation
/ statistics & numerical data
Male
Middle Aged
Neoplasm Recurrence, Local
/ epidemiology
Neoplasms, Complex and Mixed
/ mortality
Retrospective Studies
Tumor Burden
Journal
Journal of the American College of Surgeons
ISSN: 1879-1190
Titre abrégé: J Am Coll Surg
Pays: United States
ID NLM: 9431305
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
29
11
2020
accepted:
30
11
2020
pubmed:
15
12
2020
medline:
29
9
2021
entrez:
14
12
2020
Statut:
ppublish
Résumé
Combined hepatocellular-cholangiocarcinoma liver tumors (cHCC-CCA) with pathologic differentiation of both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma within the same tumor are not traditionally considered for liver transplantation due to perceived poor outcomes. Published results are from small cohorts and single centers. Through a multicenter collaboration, we performed the largest analysis to date of the utility of liver transplantation for cHCC-CCA. Liver transplant and resection outcomes for HCC (n = 2,998) and cHCC-CCA (n = 208) were compared in a 12-center retrospective review (2009 to 2017). Pathology defined tumor type. Tumor burden was based on radiologic Milan criteria at time of diagnosis and applied to cHCC-CCA for uniform analysis. Kaplan-Meier survival curves and log-rank test were used to determine overall survival and disease-free survival. Cox regression was used for multivariate survival analysis. Liver transplantation for cHCC-CCA (n = 67) and HCC (n = 1,814) within Milan had no significant difference in overall survival (5-year cHCC-CCA 70.1%, HCC 73.4%, p = 0.806), despite higher cHCC-CCA recurrence rates (23.1% vs 11.5% 5 years, p < 0.001). Irrespective of tumor burden, cHCC-CCA tumor patient undergoing liver transplant had significantly superior overall survival (p = 0.047) and disease-free survival (p < 0.001) than those having resection. For cHCC-CCA within Milan, liver transplant was associated with improved disease-free survival over resection (70.3% vs 33.6% 5 years, p < 0.001). Regardless of tumor burden, outcomes after liver transplantation are superior to resection for patients with cHCC-CCA. Within Milan criteria, liver transplant for cHCC-CCA and HCC result in similar overall survival, justifying consideration of transplantation due to the higher chance of cure with liver transplantation in this traditionally excluded population.
Sections du résumé
BACKGROUND
Combined hepatocellular-cholangiocarcinoma liver tumors (cHCC-CCA) with pathologic differentiation of both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma within the same tumor are not traditionally considered for liver transplantation due to perceived poor outcomes. Published results are from small cohorts and single centers. Through a multicenter collaboration, we performed the largest analysis to date of the utility of liver transplantation for cHCC-CCA.
STUDY DESIGN
Liver transplant and resection outcomes for HCC (n = 2,998) and cHCC-CCA (n = 208) were compared in a 12-center retrospective review (2009 to 2017). Pathology defined tumor type. Tumor burden was based on radiologic Milan criteria at time of diagnosis and applied to cHCC-CCA for uniform analysis. Kaplan-Meier survival curves and log-rank test were used to determine overall survival and disease-free survival. Cox regression was used for multivariate survival analysis.
RESULTS
Liver transplantation for cHCC-CCA (n = 67) and HCC (n = 1,814) within Milan had no significant difference in overall survival (5-year cHCC-CCA 70.1%, HCC 73.4%, p = 0.806), despite higher cHCC-CCA recurrence rates (23.1% vs 11.5% 5 years, p < 0.001). Irrespective of tumor burden, cHCC-CCA tumor patient undergoing liver transplant had significantly superior overall survival (p = 0.047) and disease-free survival (p < 0.001) than those having resection. For cHCC-CCA within Milan, liver transplant was associated with improved disease-free survival over resection (70.3% vs 33.6% 5 years, p < 0.001).
CONCLUSIONS
Regardless of tumor burden, outcomes after liver transplantation are superior to resection for patients with cHCC-CCA. Within Milan criteria, liver transplant for cHCC-CCA and HCC result in similar overall survival, justifying consideration of transplantation due to the higher chance of cure with liver transplantation in this traditionally excluded population.
Identifiants
pubmed: 33316425
pii: S1072-7515(20)32524-2
doi: 10.1016/j.jamcollsurg.2020.11.017
pmc: PMC8450541
mid: NIHMS1735541
pii:
doi:
Types de publication
Comparative Study
Evaluation Study
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
361-371Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 American College of Surgeons. Published by Elsevier Inc. All rights reserved.
Références
J Am Coll Surg. 2012 Jul;215(1):19-28; discussion 28-30
pubmed: 22608403
Am J Transplant. 2010 May;10(5):1263-7
pubmed: 20420633
Hepatology. 2001 Jun;33(6):1394-403
pubmed: 11391528
Ann Surg. 2004 Feb;239(2):265-71
pubmed: 14745336
Gastroenterology. 2012 Jul;143(1):88-98.e3; quiz e14
pubmed: 22504095
Mod Pathol. 2019 Oct;32(10):1486-1494
pubmed: 31186529
Cancer. 2002 Apr 1;94(7):2040-6
pubmed: 11932907
J Am Coll Surg. 2015 Apr;220(4):628-37
pubmed: 25728142
Liver Transpl. 2000 May;6(3):309-16
pubmed: 10827231
Cancer Imaging. 2018 Feb 27;18(1):8
pubmed: 29486800
N Engl J Med. 1996 Mar 14;334(11):693-9
pubmed: 8594428
Ann Hepatol. 2018 Oct 16;17(6):969-979
pubmed: 30600299
Ann Surg. 2014 May;259(5):944-52
pubmed: 24441817
J Surg Oncol. 2013 May;107(6):608-12
pubmed: 23386397
Hepatology. 2018 Jul;68(1):113-126
pubmed: 29360137
Hepatobiliary Pancreat Dis Int. 2017 Jun;16(3):264-270
pubmed: 28603094
J Hepatocell Carcinoma. 2019 Jul 22;6:119-129
pubmed: 31413960
Liver Transpl. 2011 Aug;17(8):934-42
pubmed: 21438129
Dig Dis Sci. 2010 Dec;55(12):3597-601
pubmed: 20848202
HPB (Oxford). 2016 Nov;18(11):886-892
pubmed: 27546172
Liver Transpl. 2018 Oct;24(10):1384-1397
pubmed: 29573187
Liver Transpl. 2001 Dec;7(12):1023-33
pubmed: 11753904
AJR Am J Roentgenol. 2016 Jul;207(1):25-31
pubmed: 26866746
Arch Surg. 2011 Jun;146(6):683-9
pubmed: 21690444
Am J Pathol. 1949 Jul;25(4):647-55
pubmed: 18152860
Liver Transpl. 2018 May;24(5):634-644
pubmed: 29514406
Transplantation. 2015 Jan;99(1):151-7
pubmed: 25029385
Liver Int. 2019 Dec;39(12):2386-2396
pubmed: 31544304